Compare Costco Wholesale Corporation (COST) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Cassava Sciences Inc — how do they compare? Costco Wholesale Corporation trades at $947.54 (market cap $420.05B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Costco Wholesale Corporation is far larger — about 10661.2× Cassava Sciences Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Cassava Sciences Inc for 37 Days on average.
| COST | FLNA | |
|---|---|---|
Market Cap | $420.05B | $39.40M |
Volume | 2,087,565 | 759,018 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $4.64 |
52-Week Low | $849.63 | $0.68 |
Typical Hold Time | 132 Days | 37 Days |
Enterprise Value | $407.33B | -$43.28M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $942.25, up 0.7% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year, and fiscal 2025 revenue reached $275.24 billion with net income of $8.10 billion. Analyst consensus is strongly bullish with a $1,090 price target, though valuation ratios like P/E of 45.39 are elevated.
The outlook remains positive due to membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid with recent beats, supporting the buy-rated sentiment, yet any market pullback could present a better entry point for long-term investors.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
